Myelodysplastic syndromes trials in Spain

In Spain 31 Also abroad 369

31 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in Spain
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Where
Barcelona, Madrid, Oviedo, Sevilla, Valencia
Age
18 years and over
People
126 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07929740 · EU 2025-524332-19-00
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Barcelona, Madrid, Pamplona
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 3Taking people
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Salamanca, Valencia
Age
18 years and over
People
225 worldwide
Run by
Takeda
See details and how to joinNCT06499285 · EU 2024-516009-22-00
Phase 3Taking people
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Salamanca, Sevilla, Valencia
Age
18 years and over
People
300 worldwide
Run by
Takeda
See details and how to joinNCT07422480 · EU 2025-523544-12-00
Phase 1/2Taking people
A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, bone marrow, lymph and lymphatic system.
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia
Age
18 years and over
People
16
Run by
Cellcentric Limited
See details and how to join2024-519498-20-00 · EU 2024-519498-20-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Barcelona, Madrid, Pamplona, Salamanca
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 1Taking people
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
78 worldwide
Run by
Genmab
See details and how to joinNCT07384715 · EU 2025-523101-15-00
Phase 1Taking people
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
Where
Cáceres, Valencia
Age
18 years and over
People
105 worldwide
Run by
Stelexis BioSciences
See details and how to joinNCT06533761 · EU 2024-518071-58-00
Phase 2Taking people
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Where
Barcelona, L'Hospitalet de Llobregat, Oviedo, Salamanca, Valencia
Age
18 years and over
People
210 worldwide
Run by
Takeda
See details and how to joinNCT04419649 · EU 2023-507469-24-00
Phase 2Taking people
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Where
Barcelona, L'Hospitalet de Llobregat, Salamanca
Age
18 years and over
People
156 worldwide
Run by
Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00
Phase 3Taking people
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Where
Badalona, Barcelona, Cáceres, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Oviedo, Pamplona, Salamanca, Sevilla, Valencia
Age
18 years and over
People
490 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00
Phase 1/2Taking people
Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS
Where
Barcelona, Cáceres, Madrid, Oviedo, Pamplona, Valencia
Age
18 years and over
People
60
Run by
Aop Orphan Pharmaceuticals GmbH
See details and how to join2025-523396-38-00 · EU 2025-523396-38-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Badalona, Barcelona, Cáceres, Girona, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo, Pamplona, Salamanca, Valencia
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 2Enrolling by invitation
RVU120 Rollover Study
Where
Pamplona
Age
18 years and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Barcelona, Madrid
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Barcelona, Salamanca, Sevilla, Valencia
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 3Taking people
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Where
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Sevilla, Valencia
Age
18 years and over
People
48 worldwide
Run by
Institut de Recherches Internationales Servier
See details and how to joinNCT06465953 · EU 2023-510155-37-00
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Barcelona, Lleida, Logroño, Madrid, Murcia
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 1/2Not yet taking people in Spain
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Barcelona, Madrid, Pamplona, Valencia
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Barakaldo, Barcelona, Madrid, Oviedo, Salamanca, Seville, Valencia
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
Phase 1/2Taking people
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Where
Badalona, Barcelona, Madrid, Pamplona, Valencia
Age
18 years and over
People
250 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT04068597
Phase 2Taking people
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Pamplona, Salamanca, Valencia
Age
18 years and over
People
80 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06847867 · EU 2024-519928-24-00
Phase 1Taking people
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Where
Barcelona, Lleida, Logrono, Madrid, Murcia, Valencia
Age
18 years and over
People
18 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04953897 · EU 2024-516291-16-00
Phase 1Taking people
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Where
Barcelona, Lleida, Logrono, Madrid, Murcia, Valencia
Age
18 years and over
People
27 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04953910 · EU 2024-516292-33-00
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Albacete, Barcelona, Cáceres, Las Palmas, Madrid, Oviedo, Salamanca, Santander, Santiago de Compostela, Valencia
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555